FAAH/MAGL-IN-5

Cat. No.:	HY-77491
CAS No.:	1010096-65-7
Molecular Formula:	$C_{17}H_{17}N_5O$
Molecular Weight:	307.35
Target:	FAAH; MAGL
Pathway:	Metabolic Enzyme/Protease; Neuronal Signaling
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (325.36 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	3.2536 mL	16.2681 mL	32.5362 mL
	5 mM	0.6507 mL	3.2536 mL	6.5072 mL
	10 mM	0.3254 mL	1.6268 mL	3.2536 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (8.13 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (8.13 mM); Clear solution

BIOLOGICAL ACTIVITY

Description	AM6701 is a potent FAAH/MAGL inhibitor (equipotent inhibitory IC_{50}: 1.2 nM) with neuroprotective effects[1].
IC_{50} & Target	IC50: 1.2 nM (FAAH/MAGL)[1]

REFERENCES

[1]. Vinogran Naidoo, et al.Equipotent inhibition of fatty acid amide hydrolase and monoacylglycerol lipase - dual targets of the endocannabinoid system to protect against seizure pathology.Neurotherapeutics.2012 Oct;9(4):801-13.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA